(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

The company's net profit per share, which was €3.83 in 2023, turned into a loss of €2.77 in 2024. The German company is ...

German biotech company BioNTech announced a loss of EURO665.3 million (USD721 million) in 2024, due to the decline of ...

German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...